Getty Images
Pfizer and BioNtech have announced that their vaccine is effective against the VOCID-19 variant that has appeared in the UK.
The US pharmaceutical company Pfizer and its German partner BioNtech announced that the COVID-19 vaccine they jointly developed is effective against the virus variant that appeared in the UK in late 2020 and has already spread throughout the UK. world. The news was confirmed this Wednesday based on lab results.
Pfizer and BioNtech announced that the study was based on ten mutations in the VOCID-19 variant known as B117, which appeared in November 2020 in the United Kingdom, much more infectious than the type of coronavirus it had previously afflicted. on the planet.
The study is signed by Ugur Sahin and Oezlem Tuereci, co-founders of the German company BioNtech. Sahin is the executive director of the company and Tuereci, his wife, serves as medical director.
More data on immune responses after the Pfizer mrna vaccine against the pseudo virus carrying Spike protein with mutations in variant B.1.1.7 (del69 / 70, del 144/145, N501Y, A570D, P681H, T716I, S982A, D1118H). There is a modest reduction in the effectiveness of vaccine sera.
– Gupta Lab, Cambridge (@GuptaR_lab) January 18, 2021
Among 15 individuals with neutralizing activity three weeks after the Pfizer mRNA vaccine, 10 showed evidence of reduced antibody efficacy against the B.1.1.7 mutant (fold change> 3). The highest folding change was 6. The mean folding change was 3.85 (IQR 2.68-5.28). pic.twitter.com/0CvN3qrYw6
– Gupta Lab, Cambridge (@GuptaR_lab) January 18, 2021
The news is encouraging for the scientific community fighting the coronavirus as it implies that vaccine development should not be restarted. The UK is going through days of deep bewilderment as it observes how mortality rates are rising due to this variation in VOCID-19.
The study with a pseudovirus from Pfizer and BioNteh
Pfizer and BioNtech have announced that their coronavirus vaccine is effective against the virus variant that appeared in late 2020 in the UK. They were based on a trial in which 16 volunteers participated.
The 16 people who participated in the Pfizer and BioNteh study had already been vaccinated against COVID-19. They were exposed to a synthetic virus classified as pseudovirus. The pseudovirus designed for this study contained the same protein as the B117 variation of the coronavirus.
The results showed that the antibodies generated by the 16 vaccinated volunteers (Comirnaty, or BNT162b2) eliminated the pseudovirus as effectively as they had defeated the proteins of the previous version of the coronavirus.
Israel questions the effectiveness of the Pfizer vaccine
The single dose of Covid vaccine in Israel “less effective than we thought” https://t.co/vowqDsY0Lr
– The Guardian (@guardian) January 19, 2021
Israel questioned whether the effectiveness of the first dose of the Pfizer and BioNtech coronavirus vaccine is as effective as the manufacturing companies have indicated.
Nachman Ash, an Israeli official in charge of designing the pandemic strategy, questioned the data provided by the companies that developed the vaccine.
“A lot of people got infected between the first and second dose of the Pfizer vaccine,” he said in a dialogue with Army Radio on Tuesday afternoon.
According to figures released by the Israeli Ministry of Health, 12,400 people tested positive for coronavirus after the first dose of the Pfizer and BioNtech vaccine was applied. Another 69 people were diagnosed with the disease after receiving the second application of the vaccine.
“It seems that the protection offered by the first dose is less effective than we had thought.” And he stressed that data on protection against the SARS-CoV-2 virus after the first dose is “lower than what Pfizer presented,” Nachman Ash added.
READ MORE: Joe Biden plans an economic stimulus for $ 1.9 trillion
Follow Chiquis Rivera on Facebook right now